Meyka Pro banner
Cerenome, Inc.

Cerenome, Inc. (NASDAQ: CNSY) Stock Competitors & Peer Comparison

See CNSY's competitors and their performance on the NASDAQ and across the wider stock market.

CNSYNASDAQ
HealthcareMedical - Pharmaceuticals
$3.84
$0.010(0.26%)
U.S. Market opens in 12h 40m

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for CNSY and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CNSY$3.84+0.26%26.4M-0.53-$7.19N/A
RPRX$57.97+2.11%25.7B11.04$5.25+1.58%
CORT$114.23+3.12%12.3B326.37$0.35N/A
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
LQDA$91.03+0.90%8.1B650.21$0.14N/A
KNSA$76.53+0.62%5.8B85.03$0.90N/A
TRLV$9.08+3.77%1.5B-21.50-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
LTGO$18.56+1.70%1.1BN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Royalty Pharma plc (NASDAQ: RPRX)

CNSY vs RPRX Comparison August 2026

Cerenome, Inc. (NASDAQ: CNSY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNSY stands at 26.4M. In comparison, RPRX has a market cap of 25.7B. Regarding current trading prices, CNSY is priced at $3.84 on the NASDAQ, while RPRX trades at $57.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNSY currently has a P/E ratio of -0.53, whereas RPRX's P/E ratio is 11.04. In terms of profitability, CNSY's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CNSY is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CNSY.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions